

Pharmaceutical Representatives:

- Reporting for Pharmaceutical Representatives, is it the individual's responsibility or the manufacturer's?
 - Both, please see below for specific requirements.
 - Manufacturers are required to submit a list of names of all pharmaceutical representatives who market prescription drugs in Nevada.
 - Section 4.6(1) of the law states "A **manufacturer** of a prescription drug shall provide to the Department a list of each pharmaceutical sales representative who markets prescription drugs on behalf of the manufacturer to providers of health care licensed, certified or registered in this State, pharmacies or employees thereof, operators or employees of medical facilities or persons licensed or certified under the provisions of title 57 of NRS and update the list at least annually."
 - Each pharmaceutical representative is required to submit a report of all compensation or prescription drug that was provided to a provider of health care licensed, certified or registered in this State, pharmacies and employees thereof, operators and employees of medical facilities and persons licensed or certified under the provisions of title 57 of NRS.
 - Section 4.6(4) of the law states "On or before March 1 of each year, **each person** who was included on a list of pharmaceutical sales representatives submitted pursuant to subsection 1 at any time during the immediately preceding calendar year shall submit to the Department a report, which must include, for the immediately preceding calendar year: (a) A list of providers of health care licensed, certified or registered in this State, pharmacies and employees thereof, operators and employees of medical facilities and persons licensed or certified under the provisions of title 57 of NRS to whom the pharmaceutical sales representative provided: (1) Any type of compensation with a value that exceeds \$10; or (2) Total compensation with a value that exceeds \$100 in aggregate; and (b) The name and manufacturer of each prescription drug for which the pharmaceutical sales representative provided a free sample to a provider of health care licensed, certified or registered in this State, pharmacy or employee thereof, operator or employee of a medical facility or person licensed or certified under the provisions of title 57 of NRS and the name of each such person to whom a free sample was provided."
 - While the law requires the individual to submit the yearly report, manufacturers may submit these yearly reports on behalf of pharmaceutical representatives in their employment.
 - Report formatting and specifics may be found by clicking [here](#).
- Does this law apply to any/all pharmaceutical representatives and not just those engaging in the sales and marketing of diabetes-related treatments?
 - Yes, this law applies to all pharmaceutical representatives.
- When we provide the list of the company's pharmaceutical sales representatives working in Nevada, is there a format that should be used?

- An excel file is preferable listing the first name, last name and company that the individual represents. An example is provided below. This information can be e-mailed to drugtransparency@dhhs.nv.gov and should be updated as changes occur within your organization.

Company	Pharmaceutical Representative First Name	Pharmaceutical Representative Last Name

Prescriptions Drug Manufacturers:

- Sections 3.8 and 4 of the law require some drug manufacturers to submit certain reports on diabetes drug price increases to DHHS by April 1, 2018. When do you anticipate that DHHS will issue the format and other requirements for these reports?
 - Regulations have been drafted and are available for review on the website http://dhhs.nv.gov/HCPWD/Drug_Transparency/
 - Report formatting and specifics may be found by clicking [here](#).

Pharmacy Benefit Managers:

- Report formatting and specifics may be found by clicking [here](#).

Consumers:

- Will this new law limit my access to drugs?
 - Senate Bill 539 does not in any way limit your access to medication. The law is intended to assist DHHS with research and analysis related to increasing costs for various medications required to treat diabetes.